AGENT FOR REDUCING MALODOR OF FLATULENCE AND/OR STOOL

Abstract

Targeted at, for example, mammalian animals including human, and for the purpose of realizing an effective reduction in the malodor inherent to flatulence and/or stool with an orally ingestible material such as an inorganic substance, provided is an orally ingestible malodor reducing agent for reducing the malodor of flatulence and/or stool, the agent containing nanosized colloidal platinum microparticles as an active ingredient.

Claims

1. An orally ingestible malodor reducing agent for reducing the malodor of flatulence and/or stool, containing platinum microparticles as an active ingredient.

2. The malodor reducing agent according to claim 1 for reducing hydrogen sulfide in flatulence and/or stool.

3. The malodor reducing agent according to claim 1, containing nanosized colloidal platinum microparticles as an active ingredient.

4. The malodor reducing agent according to claim 1, wherein the microparticles have an average particle diameter of not larger than 10 nm.

5. The malodor reducing agent according to claim 1, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

6. The malodor reducing agent according to claim 2, containing nanosized colloidal platinum microparticles as an active ingredient.

7. The malodor reducing agent according to claim 2, wherein the microparticles have an average particle diameter of not larger than 10 nm.

8. The malodor reducing agent according to claim 3, wherein the microparticles have an average particle diameter of not larger than 10 nm.

9. The malodor reducing agent according to claim 6, wherein the microparticles have an average particle diameter of not larger than 10 nm.

10. The malodor reducing agent according to claim 2, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

11. The malodor reducing agent according to claim 3, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

12. The malodor reducing agent according to claim 6, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

13. The malodor reducing agent according to claim 4, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

14. The malodor reducing agent according to claim 7, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

15. The malodor reducing agent according to claim 8, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

16. The malodor reducing agent according to claim 9, containing 1 nmole to 100 mmole of the platinum microparticles per 1,000 ml of water.

Description

MODE FOR CARRYING OUT THE INVENTION

[0025] The present invention is an orally ingestible agent for reducing the malodor of flatulence and/or stool, which contains platinum microparticles as an active ingredient.

[0026] In this specification, “platinum microparticles” refer to microparticles of platinum, and include powdery platinum microparticles such as platinum black; platinum microparticles using a protective agent; platinum microparticles not using a protective agent, but using a surfactant; platinum microparticles using neither a protective agent nor a surfactant; and single atom particles.

[0027] There are known various methods for producing platinum microparticles (e.g. Japanese Examined Patent Application Publication No. Sho 57-43125, Japanese Examined Patent Application Publication No. Sho 59-120249, Japanese Unexamined Patent Application Publication No. Hei 9-225317, Japanese Unexamined Patent Application Publication No. Hei 10-176207, Japanese Unexamined Patent Application Publication No. 2001-79382 and Japanese Unexamined Patent Application Publication No. 2001-122723); those skilled in the art can easily prepare microparticles by referring to these methods. For example, as a method for producing noble metal microparticles, there can be utilized, for example, a chemical method called precipitation method or metal salt reduction reaction method, or a physical method called combustion method. There may also be employed a liquid phase laser ablation method; and a method for conducting suspension using a surfactant, but without using a protective agent. As the malodor reducing agent of the present invention, there may be used microparticles prepared by any of these methods. A method of microparticulation is, for example, described in the specification of Japanese Patent No. 4058072; the method is thus included in the disclosure of this specification by referring to the disclosure of the captioned publication.

[0028] Further, for example, in the case of platinum microparticles using a protective agent, platinum nanoparticles can be uniformly dispersed in water, using a metal protective agent as a substance for protecting fine metal particles so that they will not aggregate. Examples of a protective agent for fine metal particles include polyvinylpyrrolidone, polyacrylic acid, pectin and citric acid; pectin and citric acid are preferred as they are food ingredients.

[0029] Further, while the platinum in the malodor reducing agent of the present invention may also be a platinum-containing alloy, preferred is platinum itself. As a metal(s) forming the alloy, there can be listed, for example, gold, ruthenium, rhodium, palladium, osmium and iridium. Together with the platinum microparticles, there may also be used a colloidal microparticle suspended substance of multiple kinds of metals including microparticles of one or more kinds of the above-listed other metals.

[0030] As the platinum microparticles, preferred are microparticles having a large specific surface area, a superior surface reactivity, and a capability of forming a colloidal state. For example, the microparticles may be those having a particle diameter of a micrometer level, or those having a particle diameter of a nano level. There are no particular restrictions on the particle diameter of the microparticles; there may be used microparticles having an average particle diameter of not larger than 50 nm, preferably not larger than 20 nm, more preferably not larger than 10 nm, particularly preferably about 1 to 6 nm. Also preferred is a dispersion liquid with these microparticles being contained in an aqueous medium in a stably suspended state. As the aqueous medium, other than water, there may be used an organic solvent that has a low toxicity to a living body and is capable of being mixed with water at any ratio, such as ethanol, ethylene glycol or the like. Preferably, water may be used as the aqueous medium.

[0031] It is preferred that the malodor reducing agent of the present invention be prepared in such a manner that, for example, about 1 nmole to 100 mmole, more preferably about 10 nmole to 50 mmole of the platinum microparticles are to be contained in a colloidal state per 1,000 ml of water. A platinum concentration is preferably about 100 to 300 ppm, particularly preferably about 200 ppm.

[0032] The malodor reducing agent containing the colloidal platinum microparticles at the above concentration can be orally administered to a mammalian animal including human. For example, by orally ingesting per day about 50 to 5,000 μl, preferably about 200 μl of the malodor reducing agent containing 200 ppm of the colloidal platinum microparticles, the malodor of flatulence and/or stool egested will be remarkably reduced due to the onset of a desired effect in the intestine. That is, an orally ingested dose of the platinum microparticles of the present invention is equivalent to 1×10.sup.−3 g at maximum per day.

[0033] As for the safety of platinum microparticles, there is a report on hepatopathy when administered intravenously (Y Yagmagishi, A. et al., Pharmazie 68:178-182, 2013). Specifically, 24 hours after intravenously administering platinum nanoparticles having a particle diameter of not larger than 1 nm and platinum nanoparticles having a particle diameter of 15 nm (sub-nanosized platinum particles; respectively referred to as snPt, nPt hereunder) to a mouse, as a result of evaluating the existence or non-existence of hepatopathy by measuring alanine aminotransferase (alanine transaminase; ALT) and aspartate aminotransferase (aspartate transaminase) that had leaked into the blood, hepatopathy was observed only in the case where snPt was administered in a dose of 15 to 20 mg/kg. Meanwhile, in the case of nPt having the particle diameter of 15 nm, hepatopathy was not observed even when administered in the same dose. This intravenous administration in the dose of 15 to 20 mg/kg is equivalent to about 1 g in the case of a human weighing 60 kg. In order for such amount of platinum microparticles to enter the body via oral ingestion, an amount of 1,000 g needs to be orally ingested given that a rate of absorption from the small intestine is 0.1% at maximum (it is indicated in the following working examples that 99.96% of the platinum microparticles of the present invention were able to be recovered in stool if orally ingested by human.). Thus, it can be understood that the oral ingestion dose of the malodor reducing agent of the present invention is highly safe.

[0034] The malodor reducing agent of the present invention can be drunk as a health food, and can also be used as a medicine itself

[0035] As a health food, for example, the malodor reducing agent containing 200 ppm of the colloidal platinum microparticles may be added to teas, juices, soft drinks and drinks, and then drunk in these forms.

[0036] If using the malodor reducing agent of the present invention as a medicine, the malodor reducing agent may not only be used as an oral liquid agent containing 200 ppm of the colloidal platinum microparticles, but also be produced as a medicinal preparation in the form of a solid preparation such as tablets, capsules, granules and powdered medicines by adding pharmaceutically allowable medicinal additives, and then administered to a patient.

[0037] As the pharmaceutically allowable medicinal additives used to produce the medicinal preparation, there may be added, for example, additives known to those skilled in the art, such as a stabilizer, antioxidant, pH adjuster, buffering agent, suspension agent, emulsifier and surfactant so as to be able to produce the medicinal preparation. The types, administrations and dosages of these medicinal additives are described in, for example, Japanese Pharmaceutical Excipients Directory 2016 (edited by IPEC Japan, published by Yakuji Nippo, Limited, February 2016); the medicinal preparation can be produced and used in accordance with these descriptions.

Working Examples

1. Production of Platinum Nanoparticles

[0038] Platinum nanoparticles were produced by a citric acid reduction method. Here, 4 ml of a 16.6 mM chloroplatinic acid (H.sub.2PtCl.sub.6) was added to 43.8 ml of water, followed by performing heating in an oil bath (oil bath). At a time point when the temperature reached 100° C., 8.6 ml of a 77.21 mM trisodium citrate (trisodium citrate; C.sub.6H.sub.5Na.sub.3O.sub.7) was added, and heating was directly continued at 100° C. for about 1 hour and 30 min until the reaction solution had turned black. Heating was stopped once the reaction solution had turned black; the temperature of the reaction solution was then lowered to room temperature, and 10 ml of water was added thereto in the end, thereby obtaining 66.4 ml of a platinum nanocolloid liquid having a platinum concentration of 1 mM. The particle diameter of the platinum microparticles was 4.7±1.5 nm.

2. Evaluation on Effect of Reducing Odor of Flatulence and Stool by Platinum Nanoparticles

[0039] Nanosized platinum microparticles were produced; after being orally ingested, the platinum metal was then recovered from stool, and a reduction in the malodor inherent to flatulence and stool was quantified.

[0040] As a platinum nanocolloid, there was used a platinum nanocolloid water as a liquid for oral ingestion that contained per 1 ml, as platinum, 180 μg of platinum microparticles having an average particle diameter of not larger than 6 nm, and substantially contained no aggregated platinum particles. There were contained 0.9560% of the platinum nanocolloid (platinum; 0.00019%, trisodium citrate 0.0028%), 0.0045% of citric acid and 99.0395% of water; a platinum content was 172±1.5 ppm, and pH was 3.71.

[0041] There is ensured such a safety that when ingested orally, the nanosized platinum microparticles (4.7±1.5 nm) reduced by citric acid and directly employing such citric acid as a protective agent are barely absorbed from digestive canal before arriving at the large intestine, and 99.96% of them will then be egested into stool. The malodor of flatulence and stool before orally ingesting the nanosized platinum metal particles; and the malodor of flatulence and stool three weeks after starting to orally ingest the nanosized platinum metal particles were quantified and compared using a monitor GT300-VOC (distributor: MK Scientific, Inc.) capable of sensitively detecting volatile organic compounds (Volatile Organic Compounds; VOC), smokes, odors or the like, particularly ammonia, toluene and hydrogen sulfide, and displaying a quantified value(s) via CIAQ (Composite Index of Air Quality) where changes in the odors in the air are collectively evaluated with a fresh air being 1. As a result of orally ingesting the nanosized platinum microparticles at a ratio of 40 μg/day per a human body weight of 60 kg for three weeks, the numerical value measured by the odor monitor significantly decreased at a risk rate (p) of lower than 0.01% after orally ingesting the nanosized platinum metal particles for three weeks; it was indicated that the malodor of flatulence and stool had been statistically significantly reduced by orally ingesting the nanosized platinum microparticles (Table 1). Here, the statistical analysis was conducted using Student's t-test.

TABLE-US-00001 TABLE 1 Statistically significant Experimental group Measured value difference Flatulence Before oral ingestion 79.3 ± 64.0 (n = 27) p < 0.01 odor Three weeks after 10.9 ± 10.2 (n = 12) starting oral ingestion Stool odor Before oral ingestion 7.43 ± 1.18 (n = 7)  p < 0.01 Three weeks after 0.57 ± 0.49 (n = 7)  starting oral ingestion

3. Evaluation on Effect of Reducing Hydrogen Sulfide in Stool

[0042] A gas sampling pump kit (model GV100S) manufactured by GASTEC CORPORATION was used to measure, quantify and compare ammonia and hydrogen sulfide dispersed from stool before and after orally ingesting the nanosized platinum microparticles.

[0043] Specifically, 100 to 200 g of human stool was weighed out and put into an enamel bedpan, followed by swiftly covering the same with Press'n Seal (by The Glad Products Company) so as to keep maintaining an airtightness; about 3 min later, the concentrations (ppm) of the gases held over the bedpan were quantified using corresponding detecting tubes.

[0044] As a result of conducting measurement after a week or later since starting to orally ingest the nanosized platinum microparticles at the ratio of 40 μg/day per the human body weight of 60 kg, while no changes were observed in the ammonia concentration, the hydrogen sulfide concentration had statistically significantly decreased at a risk rate (p) of lower than 0.01%; it was indicated that by orally ingesting the nanosized platinum microparticles, the malodor of stool was able to be reduced at least through a reduction in hydrogen sulfide (Table 2). Here, the statistical analysis was conducted using Student's t-test.

TABLE-US-00002 TABLE 2 Measured results of concentrations of ammonia and hydrogen sulfide dispersed from stool Ammonia (ppm/g) Hydrogen sulfide (ppm/g) Before oral 1.69 ± 0.48 (n = 6)  5.88 ± 0.96 (n = 6) ingestion After oral 2.47 ± 1.16 (n = 9) **1.77 ± 0.69 (n = 10) ingestion **p < 0.01